Senior Scientist/Associate Director of Translational Medicine

Company Summary:


Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. Leap has a strong financial position and in September 2021 closed a public offering with gross proceeds to Leap of approximately $104 million.  Leap is based in Cambridge, MA.  For more information about Leap Therapeutics, visit

Reporting to the Senior Director of Translational Medicine, Leap Therapeutics  is seeking a highly motivated individual with excellent communication skills to join our translational team.  The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology biomarkers.  The candidate will collaborate with multiple functional teams, including research and clinical development, to ensure that the clinical biomarker strategy is effectively implemented with timely delivery of results. 

Key Responsibilities:

  • Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action

  • Independently design, execute and manage translational research activities from discovery through clinical development

  • Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation

  • Work closely with the research team to identify novel biomarkers

  • Integrate biomarker and clinical data to guide patient stratification

  • Manage CROs responsible for the generation of both exploratory and clinical biomarker data

  • Transition research assays to LDTs and contribute to CDx development

  • Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols

  • Function as a scientific thought leader inside the company for cutting edge biomarker approaches



  • PhD in cancer biology, immunology, genomics, biochemistry or molecular/cellular biology

  • 5+ years of pharmaceutical or biotechnology industry experience in oncology or cancer immunotherapy with an emphasis on translational research and clinical biomarkers

  • Proven track record of transitioning biomarkers from the bench to the clinic

  • Strong knowledge of immuno-oncology and associated biomarker approaches

  • Experience managing CROs

  • Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs

  • Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets

  • Excellent communication skills and the ability present results in a clear and concise manner

  • Excellent interpersonal skills, personal integrity, professional manner and ability to gain respect and develop good working relationships with cross functional personnel at all levels

  • Experience with Wnt signaling or other cancer cell signaling pathways is preferred

  • Familiarity with multiplex techniques such as NanoString DSP and mIF is a plus

  • Experience with digital image analysis techniques for stained pathology slides is preferred



Leap Therapeutics is an Equal Opportunity Employer committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status.